On 17 October 2019, orphan designation EU/3/19/2211 was granted by the European Commission to Therapharm Deutschland GmbH, Germany, for besilesomab for treatment in haematopoietic stem cell transplantation.
|Disease / condition||
Treatment in haematopoietic stem cell transplantation
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: